mRNA has been reported (Lipska et al. 2006). Presumably differences in the demographic
characteristics, drug treatment, methodology, and composition of brain tissue samples
including the ratio of white vs gray matter may actually account for these apparent
discrepancies. The later point is highlighted by our more recent studies that identified
GAD67 and reelin downregulation occurring specifically in GABAergic interneurons of
layer I and II (Ruzika et al. 2007, Veldic et al. 2007) suggesting that different cell
populations within the same brain areas may have a quite distinct GABAergic deficit profile.
At the molecular level, in addition to reelin, brain-derived neurotrophic factor (BDNF) could
be a potential mediator of the reduction of the neuropil expression detected in the prefrontal
cortex (PFC) of SZ and BP disorder patients (Lewis et al., 2005). BDNF stimulates the
growth of dendrites and increases spine density on dendrites of cortical pyramidal neurons
(McAllister et al., 1996). The expression of BDNF mRNA and protein is lower in the PFC
of subjects with SZ (for a review see Roth et al. 2009) and BDNF levels and spine density
on the basilar dendrites of deep layer 3 pyramidal neurons are positively correlated in SZ
patients (Hill et al., 2005). It is important to mention that in SZ patients, reduced BDNF
expression in pyramidal neurons is accompanied by a significant decrease in TrkB mRNA
levels in GABAergic interneurons (Lewis et al., 2005). Therefore, reduced levels of BDNF
and TrkB as well as reelin may be required to produce the decrease in spine density
observed in the brain of SZ patients.
An important new finding is that the selective partial elimination of the essential NR1
subunit of the NMDA receptor in GABAergic cortical and hippocampal neurons of mice
during early adolescence generates a phenotype characteristic of the GABAergic pathology
in SZ (decreased GAD67, decreased parvalbumin, disinhibition of cortical excitatory
neurons, reduced neuronal synchrony, and SZ-like behaviors) (Belforte et al., 2010).
GABAergic neuropathologies could explain the disturbance of the reciprocal interaction
between GABAergic interneurons and principal glutamatergic pyramidal neurons that likely
underlies the appearance of the positive and negative symptoms and cognitive dysfunctions
seen in psychotic patients (Lewis and Gonzales-Burgos, 2008, Lisman et al., 2008). We and
others have suggested that SZ and BP disorder are diseases characterized by a deficit of
GABAergic transmission with consequent glutamatergic and monoaminergic network
dysfunction (Benes et al., 2007, Guidotti et al., 2005, 2009, Lewis and Gonzalez-Burgos,
2008, Lisman et al., 2008, Moghaddam, 2003, Woo et al., 2004).NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptIs an altered epigenetic regulation of gene expression the molecular
mechanism mediating the GABAergic and glutamatergic dysfunction in SZand BP disorder?
In SZ and BP disorder patients, the downregulation of GAD67, reelin, and other genes
expressed in GABAergic neurons could be a sign of a genetic abnormality. Although a
highly conserved single nucleotide polymorphism (SNP) has been identified in the vicinity
of the regulatory region of GAD67 (Straub et al., 2007) and of the reelin gene (Shifman et
DNA methylation and demethylation神经疾病靶点_生物学_自然科学_专业资料。Pharmacological...Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuroph...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
热门文档